These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30040928)

  • 21. Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
    Yang SY; Taanman JW; Gegg M; Schapira AHV
    Hum Mol Genet; 2022 Jul; 31(14):2396-2405. PubMed ID: 35179198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progressive degeneration of dopamine neurons in 6-hydroxydopamine rat model of Parkinson's disease does not involve activation of caspase-9 and caspase-3.
    Ebert AD; Hann HJ; Bohn MC
    J Neurosci Res; 2008 Feb; 86(2):317-25. PubMed ID: 17787016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dimethyl fumarate attenuates 6-OHDA-induced neurotoxicity in SH-SY5Y cells and in animal model of Parkinson's disease by enhancing Nrf2 activity.
    Jing X; Shi H; Zhang C; Ren M; Han M; Wei X; Zhang X; Lou H
    Neuroscience; 2015 Feb; 286():131-40. PubMed ID: 25449120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
    Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
    Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease.
    Khan MM; Ahmad A; Ishrat T; Khan MB; Hoda MN; Khuwaja G; Raza SS; Khan A; Javed H; Vaibhav K; Islam F
    Brain Res; 2010 Apr; 1328():139-51. PubMed ID: 20167206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of sodium butyrate in 6-OHDA induced neurotoxicity and behavioral abnormalities: Modulation of histone deacetylase activity.
    Sharma S; Taliyan R; Singh S
    Behav Brain Res; 2015 Sep; 291():306-314. PubMed ID: 26048426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long Noncoding RNA POU3F3 and α-Synuclein in Plasma L1CAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson's Disease.
    Zou J; Guo Y; Wei L; Yu F; Yu B; Xu A
    Neurotherapeutics; 2020 Jul; 17(3):1104-1119. PubMed ID: 32236821
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin.
    Santiago RM; Barbiero J; Gradowski RW; Bochen S; Lima MM; Da Cunha C; Andreatini R; Vital MA
    Behav Brain Res; 2014 Feb; 259():70-7. PubMed ID: 24183944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease.
    Yildirim FB; Ozsoy O; Tanriover G; Kaya Y; Ogut E; Gemici B; Dilmac S; Ozkan A; Agar A; Aslan M
    Neurochem Int; 2014 Dec; 79():1-11. PubMed ID: 25263280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats.
    Ferrigno A; Vairetti M; Ambrosi G; Rizzo V; Richelmi P; Blandini F; Fuzzati-Armentero MT
    Clin Exp Pharmacol Physiol; 2015 Jun; 42(6):695-703. PubMed ID: 25904005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A modulator of wild-type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson's disease.
    Burbulla LF; Jeon S; Zheng J; Song P; Silverman RB; Krainc D
    Sci Transl Med; 2019 Oct; 11(514):. PubMed ID: 31619543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation.
    Yang SY; Gegg M; Chau D; Schapira A
    Neurobiol Dis; 2020 Feb; 134():104620. PubMed ID: 31634558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased glucocerebrosidase activity and substrate accumulation of glycosphingolipids in a novel GBA1 D409V knock-in mouse model.
    Polinski NK; Martinez TN; Gorodinsky A; Gareus R; Sasner M; Herberth M; Switzer R; Ahmad SO; Cosden M; Kandebo M; Drolet RE; Buckett PD; Shan W; Chen Y; Pellegrino LJ; Ellsworth GD; Dungan LB; Hirst WD; Clark SW; Dave KD
    PLoS One; 2021; 16(6):e0252325. PubMed ID: 34106956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.
    Rocha EM; Smith GA; Park E; Cao H; Graham AR; Brown E; McLean JR; Hayes MA; Beagan J; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Antioxid Redox Signal; 2015 Aug; 23(6):550-64. PubMed ID: 26094487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
    Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
    Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
    McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
    J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alterations in primary motor cortex neurotransmission and gene expression in hemi-parkinsonian rats with drug-induced dyskinesia.
    Lindenbach D; Conti MM; Ostock CY; Dupre KB; Bishop C
    Neuroscience; 2015 Dec; 310():12-26. PubMed ID: 26363150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.
    Kumar A; Sharma N; Gupta A; Kalonia H; Mishra J
    Brain Res; 2012 Aug; 1471():13-22. PubMed ID: 22789904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial effect of etazolate on depression-like behavior and, learning, and memory impairment in a model of Parkinson's disease.
    Alzoubi KH; Mokhemer E; Abuirmeileh AN
    Behav Brain Res; 2018 Sep; 350():109-115. PubMed ID: 29758248
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methylparaben protects 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells and improved behavioral impairments in mouse model of Parkinson's disease.
    Kopalli SR; Noh SJ; Koppula S; Suh YH
    Neurotoxicology; 2013 Jan; 34():25-32. PubMed ID: 23068419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.